Key result
Impella-supported high-risk PCI proves feasible in patients over 75 despite higher 1-year mortality.
Why the study?
The impact of age on the outcomes of patients undergoing high-risk percutaneous coronary intervention supported by Impella is limited.
What are the characteristics and outcomes of patients ≥75 years of age undergoing Impella-supported high-risk percutaneous coronary intervention?
What are the characteristics and outcomes of patients ≥75 years of age undergoing Impella-supported high-risk percutaneous coronary intervention?
Impella-supported high-risk PCI is feasible in older patients (≥75 years) with an acceptable safety profile, though advanced age remains a significant predictor of 1-year mortality.
Background: In patients undergoing high-risk percutaneous coronary intervention, Impella has become an important adjunctive tool to support revascularization. The impact of age on the outcomes of patients undergoing high-risk percutaneous coronary intervention is limited. The aim of this study is to describe the characteristics and outcomes of patients ≥75 years of age undergoing Impella-supported high-risk percutaneous coronary intervention. Conclusions: Impella-supported high-risk percutaneous coronary intervention in older patients is feasible with an acceptable safety profile. However, age ≥75 years remained a statistically significant predictor for all-cause death at 1 year. Registration: URL: https://clinicaltrials.gov; Unique Identifier: NCT04136392.
No takes yet. Share an insight, caveat, or question.
Jakob et al. (2025) studied this question. Impella-supported high-risk PCI in patients aged ≥75 years is feasible and safe, but age ≥75 predicts significantly higher 1-year all-cause mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: